High dose rate brachytherapy in nonmelanoma skin cancer—Systematic review

Krzysztofiak, Tomasz; Kamińska‐Winciorek, Grażyna; Pilśniak, Aleksandra; Wojcieszek, Piotr

doi:10.1111/dth.15675

Cited by 5 publications

(2 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A primary characteristic of HDR-BT is the rapid and sharp dose fall-off, resulting in more focus on the target and less exposure to surrounding skin. 1,2 The cosmetic outcome is proven to be satisfactory. The Freiburg flap (FF) applicator, which is a flexible mesh-style surface module formed by 1 cm diameter spheres with catheters tunneled through, is widely used.…”

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

Quantitative study on dose distribution of Freiburg flap for keloid high‐dose‐rate brachytherapy based on MatriXX

Ni,

Gan,

2023

J Applied Clin Med Phys

View full text Add to dashboard Cite

PurposeTo quantify the dose distribution effect of insufficient scattering conditions in keloid HDR brachytherapy with Freiburg fFlap (FF) applicator.Materials and MethodsA phantom composed of FF applicator, MatriXX and solid water slices was designed and scanned for treatment planning. Bolus with different thicknesses were covered to offer different scatter conditions. Planar dose distributions were measured by MatriXX. The maximum value (Max), average value (Avg) and γ passing rate (3 mm/3%) were evaluated by the software MyQA Platform.ResultsThe maximum and average doses measured by MatriXX were lower than the calculated values. The difference increased as field size decreased. The Max value, found at 0.86 cm level in the two tube case, was ‐20.0%, and the avg value was ‐11.9%. All the γ values were less than 95%. This difference gradually decreased with increasing bolus thickness and the γ values were significantly improved.ConclusionMatriXX could be used for dose verification of HDR brachytherapy with an FF applicator. When the FF applicator was applied for keloid, insufficient scattering conditions would cause an insufficient target dose. This difference could be reduced by covering the bolus with different thicknesses on the applicator. The smaller the field, the thicker the bolus required.

show abstract

Section: Introductionmentioning

confidence: 98%

“…High‐dose‐rate brachytherapy(HDR‐BT)is a well‐recognized modality for keloid treatment after surgery in the clinic. A primary characteristic of HDR‐BT is the rapid and sharp dose fall‐off, resulting in more focus on the target and less exposure to surrounding skin 1,2 . The cosmetic outcome is proven to be satisfactory.…”

Section: Introductionmentioning

confidence: 99%

Quantitative study on dose distribution of Freiburg flap for keloid high‐dose‐rate brachytherapy based on MatriXX

Ni,

Gan,

2023

J Applied Clin Med Phys

View full text Add to dashboard Cite

show abstract

Basal Cell Carcinoma After High Dose Rate Brachytherapy: Medium-term Dermoscopic Evaluation of Cancer’s Response

Krzysztofiak,

Suchorzepka,

Tukiendorf

et al. 2023

Dermatol Ther (Heidelb)

Self Cite

View full text Add to dashboard Cite

Introduction Basal cell carcinoma of the facial region remains a challenge for contemporary oncology due to the presence of aesthetic regions and critical organs. Surgery is not always the optimal solution, and high dose rate (HDR) brachytherapy has emerged as an organ-sparing treatment method whose effectiveness has been proven by a growing number of publications. Dermoscopy is a diagnostic tool that bridges clinical and pathological examination of skin lesions. It is routinely used for diagnosis, monitoring of treatment, and post-treatment evaluation; however, the literature lacks data concerning changes in dermoscopic patterns of skin cancers during and after irradiation. Methods Our team conducted a prospective non-randomized trial of 39 patients with high-risk basal cell carcinomas (BCCs), mostly localized within the high-risk zone (H-zone) of the facial region, and who qualified for HDR brachytherapy. HDR contact brachytherapy with custom-made surface molds was introduced, delivering a dose of 45 Gy in 9 fractions prescribed to the tumor. Every patient was observed clinically and dermoscopically at three observational points: before treatment, at the end of treatment (3rd week), and 24 weeks after the end of therapy. The evolution of clinical and dermoscopic patterns was observed by two independent dermoscopists using current diagnostic criteria. A database of 12,088 photographic observations was evaluated. Results Univariate logistic regression proved that brachytherapy decreases the number of clinical and dermoscopic patterns typical for basal cell carcinoma, as well as dermoscopic features not related to BCC, presumably due to the formation of scar tissue. In addition, univariate logistic regression with random effects proved a positive correlation between tumor size and presence of various dermoscopic patterns typical for BCC. Conclusion Dermoscopy is proven to be easy to perform and an adequate monitoring tool for patients with BCCs undergoing HDR brachytherapy.

show abstract

Extensive head and neck skin cancers: Carcinologic surgery as a cornerstone of treatment

Bondi,

Chaine,

Foy

et al. 2024

Journal of Stomatology, Oral and Maxillofacial Surgery

View full text Add to dashboard Cite

High dose rate brachytherapy in nonmelanoma skin cancer—Systematic review

Cited by 5 publications

References 41 publications

Quantitative study on dose distribution of Freiburg flap for keloid high‐dose‐rate brachytherapy based on MatriXX

Quantitative study on dose distribution of Freiburg flap for keloid high‐dose‐rate brachytherapy based on MatriXX

Basal Cell Carcinoma After High Dose Rate Brachytherapy: Medium-term Dermoscopic Evaluation of Cancer’s Response

Extensive head and neck skin cancers: Carcinologic surgery as a cornerstone of treatment

Contact Info

Product

Resources

About